Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial | Synapse
April 28, 2025Open Access
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial
Key Points
Key points are not available for this paper at this time.
Abstract
Cancer Research UK, Lymphoma Research Trust, Lymphoma Association, and Roche.